BridgeBio Pharma Inc

BridgeBio Pharma Inc

BBIO

Get informed when a big investor buys or sells

+ Follow
Market Cap$12.8B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
BridgeBio Pharma IncBridgeBio Pharma Inc-18.3-28%21.6-1
$111.90

Target Price by Analysts

72.3% upsideBridgeBio Pharma Target Price DetailsTarget Price
$-76.74

Current Fair Value

218.2% downside

Overvalued by 218.2% based on the discounted cash flow analysis.

Share Statistics

Market cap$12.80 Billion
Enterprise Value$14.62 Billion
Dividend Yield$- (-)
Earnings per Share$-3.79
Beta0.97
Outstanding Shares195,785,884

Return

Return on Equity27.68%ROE
Return on Assets-57.20%
Return on Invested Capital-186.30%

Valuation & Multiples

P/E Ratio-18.25P/E Ratio
PEG111.85PEG
Price to Sales21.65Price to Sales
Price to Book Ratio-5.0Price to Book Ratio
Enterprise Value to Revenue21.57
Enterprise Value to EBIT-24.03
Enterprise Value to Net Income-21
Total Debt to Enterprise0.17
Debt to Equity-0.99Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 10, 2026
EPS Estimate
$-0.58
Average shareholder expectation
Revenue Estimate
$220.91 M
Average shareholder expectation

Next Earnings Call

Expected Date
October 28, 2026
EPS Estimate
$-0.57
Average shareholder expectation
Revenue Estimate
$281.65 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.0000▼ 16.52%
Total Calls-▼ 100.00%
Total Puts-▼ 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %0.01%▼ 100.28%
Total Invested$768,480▼ 99.99%
Investors Holding12▼ 501.00%

ESG Score

No data

About BridgeBio Pharma Inc

CEO: Neil Kumar